The effect of Medicare Part D on drug and medical spending

New England Journal of Medicine

Volumn 361, Issue 1, 2009, Pages 52-61

  Zhang, Yuting ^a   Donohue, Julie M ^a   Lave, Judith R ^a   O'Donnell, Gerald ^b   Newhouse, Joseph P ^c,d,e  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b Highmark Inc   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; ANTILIPEMIC AGENT;

AGED; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG COST; DRUG USE; FEMALE; HEALTH CARE COST; HEALTH CARE FINANCING; HEALTH CARE POLICY; HEALTH INSURANCE; HEALTH PROGRAM; HOSPITAL COST; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; MEDICAL FEE; MEDICARE; OUTCOME ASSESSMENT; POPULATION RESEARCH; PRESCRIPTION; PRIORITY JOURNAL;

EID: 67649662377     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMsa0807998     Document Type: Article

References (27)

1. Issues in designing a prescription drug benefit for Medicare. Washington, DC: Congressional Budget Office, October 2002. (Accessed June 8, 2009, at http://www.cbo.gov/ftpdocs/39xx/doc3960/ 10-30-PrescriptionDrug.pdf.)
2. Fortess EE, Soumerai SB, McLaughlin TJ, Ross-Degnan D. Utilization of essential medications by vulnerable older people after a drug benefit cap: importance of mental disorders, chronic pain, and practice setting. J Am Geriatr Soc 2001; 49:793-797 (Pubitemid 32652474)
3. Soumerai SB, Ross-Degnan D, Avorn J, McLaughlin TJ, Chodnovsky I. Effects of Medicaid drug payment limits on admission to hospitals and nursing homes. N Engl J Med 1991;325:1072-1077
4. Heisler M, Langa KM, Eby EL, Fendrick AM, Kabeto MU, Piette JD. The health effects of restricting prescription medication use because of cost. Med Care 2004;42:626-634
5. Gaynor M, Li J, Vogt WB. Substitution, spending offsets, and prescription drug benefit design. Forum for Health Economics & Policy 2007;10:1-31.
6. Tamblyn R, Laprise R, Hanley JA, et al. Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA 2001;285:421-429 (Pubitemid 32097260)
7. Stuart B, Doshi JA, Briesacher B, Wrobel MV, Baysac F. Impact of prescription coverage on hospital and physician costs: a case study of Medicare beneficiaries with chronic obstructive pulmonary disease. Clin Ther 2004;26:1688-1699 (Pubitemid 39643030)
8. Hsu J, Price M, Huang J, et al. Unintended consequences of caps on Medicare drug benefits. N Engl J Med 2006;354: 2349-2359 (Pubitemid 43801280)
9. Choudhry NK, Avorn J, Antman EM, Schneeweiss S, Shrank WH. Should patients receive secondary prevention medications for free after a myocardial infarction? An economic analysis. Health Aff (Millwood) 2007;26:186-194
10. Rosen AB, Hamel MB, Weinstein MC, Cutler DM, Fendrick AM, Vijan S. Costeffectiveness of full Medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes. Ann Intern Med 2005;143:89-99. (Pubitemid 41001419)
11. Field TS, Gilman BH, Subramanian S, Fuller JC, Bates DW, Gurwitz JH. The costs associated with adverse drug events among older adults in the ambulatory setting. Med Care 2005;43:1171-1176 (Pubitemid 43012173)
12. Curtis LH, Østbye T, Sendersky V, et al. Inappropriate prescribing for elderly Americans in a large outpatient population. Arch Intern Med 2004;164:1621-1625
13. March 2008 baseline: Medicare. Washington, DC: Congressional Budget Office, March 2008. (Accessed June 8, 2009, at http://www.cbo.gov/budget/ factsheets/2008b/medicare.pdf.)
14. Cook TD, Campbell DT. Quasi-experimentation: design and analysis issues for field settings. Boston: Houghton Mifflin, 1979.
15. Fact sheet: the Medicare prescription drug benefit. Washington, DC: Henry J. Kaiser Family Foundation, 2007. (Accessed June 8, 2009, at http://www.kff.org/ medicare/upload/7044-05.pdf.)
16. Producer Price Index industry data. Washington, DC: Bureau of Labor Statistics, 2008. (Accessed June 8, 2009, at http://data.bls.gov/PDQ/outside. jsp?survey=pc.)
17. LIPID Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-1357 (Pubitemid 28509344)
18. Shetty S, Secnik K, Oglesby AK. Relationship of glycemic control to total diabetes-related costs for managed care health plan members with type 2 diabetes. J Manag Care Pharm 2005;11:559-564
19. The CDC Diabetes Cost-Effectiveness Group. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA 2002;287: 2542-2551
20. Pope GC, Kautter J, Ellis RP, et al. Risk adjustment of Medicare capitation payments using the CMS-HCC model. Health Care Financ Rev 2004;25:119-141 (Pubitemid 39201560)
21. Hirano K, Imbens GW. Estimation of causal effects using propensity score weighting: an application to data on right heart catheterization. Health Serv Outcomes Res Methodol 2001;2:259-278
22. Kurth T, Walker AM, Glynn RJ, et al. Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect. Am J Epidemiol 2006;163:262-270 (Pubitemid 43145754)
23. Sato T, Matsuyama Y. Marginal structural models as a tool for standardization. Epidemiology 2003;14:680-686 (Pubitemid 40417015)
24. Li F, Zaslavsky AM, Landrum MB. Propensity score analysis with hierarchical data. In: Proceedings of the American Statistical Association Joint Statistical Meetings, Salt Lake City, Utah, July 29-August 2, 2007.
25. Medicare chartbook. 3rd ed. Washington, DC: Henry J. Kaiser Family Foundation, 2005. (Accessed June 8, 2009, at http://www.kff.org/medicare/upload/ Medicare-Chart-Book-3rd-Edition-Summer- 2005-Report.pdf.)
26. Gold M. Medicare+Choice: an interim report card. Health Aff (Millwood) 2001; 20(4):120-138 (Pubitemid 33710328)
27. Madden JM, Graves AJ, Zhang F, et al. Cost-related medication nonadherence and spending on basic needs following implementation of Medicare Part D. JAMA 2008;299:1922-1928 (Pubitemid 351574922)